Skip to main content

Advertisement

Table 4 Univariate and multivariate analyses of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) in relation to clinical parameters

From: Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis

Univariate survival analysis
  OS DFS PFS
Variables N HR 95% CI p N HR 95% CI p N HR 95% CI p
LipB mRNA RQ             
Low vs high tertile 92 1.6 0.7-3.3 0.220 64 2.5 1.1-5.6 0.020 88 2.2 1.1-4.3 0.030
LipB IHC             
Continuous 92 1.4 0.6-3.3 0.400 67 0.99 0.3-2.4 0.980 91 1.3 0.6-2.8 0.499
LipB IHC             
Categoric             
IHC = 2 vs IHC ≤ 1 92 0.8 0.4-1.6 0.604 67 0.81 0.4-1.6 0.552 91 0.9 0.5-1.7 0.892
IHC = 3 vs IHC ≤ 1   1.7 0.7-3.7 0.183   1.15 0.4-2.9 0.764   1.4 0.6-3.1 0.353
Age (years)             
>60 vs ≤60 92 2.0 1.1-3.7 0.017 67 1.15 0.6-2.1 0.660 91 1.85 1.1-3.2 0.026
FIGO stage             
III-IV vs I-II 92 8.1 2.5-26.2 <0.01 67 6.6 2.5-17.1 <0.01 91 7.8 2.8-21.7 <0.01
Residual tumor (cm)             
RT > 0 vs RT = 0 92 3.7 1.8-7.8 <0.01 67 2.4 1.2-4.6 0.010 91 3.4 1.7-6.5 <0.01
Presence of ascites             
Yes vs no 92 2.6 1.4-5.1 0.003 67 2.8 1.4-5.4 0.002 91 2.6 1.4-4.7 <0.01
Lymph node involvement             
Positive vs negative 73 1.9 0.9-4.0 0.04 58 3.4 1.7-6.7 0.001 73 2.8 1.4-5.2 0.002
Multivariate survival analysis
Variables OS DFS PFS
N HR 95% CI p N HR 95% CI p N HR 95% CI p
LipB mRNA RQ             
Low vs high tertile 92 1.8 0.9-3.9 0.103 64 3.9 1.7-9.1 0.001 88 2.8 1.4-5.8 0.004
FIGO stage             
III-IV vs I-II 92 5.1 1.2-20.5 0.022 67 13.7 4.3-43.2 <0.01 91 5.8 1.7-19.4 0.004
Residual tumor (cm)             
RT > 0 vs RT = 0 92 1.1 0.4-2.9 0.799 67 4.9 0.07-0.57 0.003 91 1.02 0.4-2.3 0.964
Presence of ascites             
Yes vs no 92 1.6 0.8-3.4 0.180 67 3.3 1.3-8.3 0.009 91 1.8 0.9-3.6 0.095